Literature DB >> 30230534

Comprehensive transcriptome profiling in elderly cancer patients reveals aging-altered immune cells and immune checkpoints.

Yingcheng Wu1, Jinhuan Wei1, Xia Chen1, Yongwei Qin2, Renfang Mao3, Jian Song1, Yihui Fan1,2.   

Abstract

Aging is the single most significant risk factor for cancer development. However, the potential impact of aging on cancer microenvironment remains poorly understood. Here, we performed a pan-cancer transcriptome analysis to identify aging-specific molecular patterns across 18 cancer types. Strikingly, aging-specific molecular features define human cancers into two types, including the strong and weak aging-effect groups. Significant aging associated molecular signature was observed in 16 cancer types (strong aging-effect group) such as breast invasive carcinoma and acute myeloid leukemia. In such 16 cancer types, old patients showed obvious poor survival compared to young patients, but this observation was not found in the weak aging-effect cancers. Aging-associated cancer-relevant molecules significantly enriched in 23 pathways including EMT and KRAS signaling. More interestingly, in cancer microenvironment, aging significantly restrains adaptive immunity, but strikingly, increases the number of infiltrated innate immune cells. Further analysis shows that the expression of immune checkpoints including PD-1, PD-L1, PD-L2 and CTLA-4 are mostly correlated with age. In general, cancer cells in elderly patients show a more aggressive phenotype and their surrounding microenvironment is under a more immune suppression status compared to young patients. Our study provides a systematic understanding of aging-associated molecular features in pan-cancer and indicates a clinical requirement to develop aging-specific therapeutic strategies in a majority of cancer types. Furthermore, aging-altered immune cells and immune checkpoints should be considered in cancer immunotherapy.
© 2018 UICC.

Entities:  

Keywords:  PD-1; aging; cancer; immune checkpoints; immunotherapy

Mesh:

Year:  2018        PMID: 30230534     DOI: 10.1002/ijc.31875

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  Predictive value of serum VEGF levels for elderly patients or for patients with poor performance status receiving anti-PD-1 antibody therapy for advanced non-small-cell lung cancer.

Authors:  Ryota Shibaki; Shuji Murakami; Yuki Shinno; Yuji Matsumoto; Tatsuya Yoshida; Yasushi Goto; Shintaro Kanda; Hidehito Horinouchi; Yutaka Fujiwara; Nobuyuki Yamamoto; Noboru Yamamoto; Yuichiro Ohe
Journal:  Cancer Immunol Immunother       Date:  2020-03-10       Impact factor: 6.968

2.  An integrative analysis of the age-associated multi-omic landscape across cancers.

Authors:  Kasit Chatsirisupachai; Tom Lesluyes; Luminita Paraoan; Peter Van Loo; João Pedro de Magalhães
Journal:  Nat Commun       Date:  2021-04-20       Impact factor: 14.919

3.  Multi-omics analysis reveals the genetics and immune landscape of dexamethasone responsive genes in cancer microenvironment.

Authors:  Yu Shen; Ying C Wu; Lixiong Gu
Journal:  Ann Transl Med       Date:  2020-11

4.  Evaluating the impact of age on immune checkpoint therapy biomarkers.

Authors:  Rossin Erbe; Zheyu Wang; Sharon Wu; Joanne Xiu; Neeha Zaidi; Jennifer La; David Tuck; Nathanael Fillmore; Nicolas A Giraldo; Michael Topper; Stephen Baylin; Marc Lippman; Claudine Isaacs; Reva Basho; Ilya Serebriiskii; Heinz-Josef Lenz; Igor Astsaturov; John Marshall; Josephine Taverna; Jerry Lee; Elizabeth M Jaffee; Evanthia T Roussos Torres; Ashani Weeraratna; Hariharan Easwaran; Elana J Fertig
Journal:  Cell Rep       Date:  2021-08-24       Impact factor: 9.423

5.  Upregulated PD-1 signaling antagonizes glomerular health in aged kidneys and disease.

Authors:  Jeffrey W Pippin; Natalya Kaverina; Yuliang Wang; Diana G Eng; Yuting Zeng; Uyen Tran; Carol J Loretz; Anthony Chang; Shreeram Akilesh; Chetan Poudel; Hannah S Perry; Christopher O'Connor; Joshua C Vaughan; Markus Bitzer; Oliver Wessely; Stuart J Shankland
Journal:  J Clin Invest       Date:  2022-08-15       Impact factor: 19.456

6.  Identification of Age-Associated Transcriptomic Changes Linked to Immunotherapy Response in Primary Melanoma.

Authors:  Nehal Farid El-Helbawy; Ahmed Ezat El Zowalaty
Journal:  Curr Issues Mol Biol       Date:  2022-09-07       Impact factor: 2.976

7.  Preoperative Factors Associated with Extrathyroidal Extension in Papillary Thyroid Cancer.

Authors:  Chi-Yu Kuo; Po-Sheng Yang; Ming-Nan Chien; Shih-Ping Cheng
Journal:  Eur Thyroid J       Date:  2020-04-14

8.  Alterations in Immune-Related Genes as Potential Marker of Prognosis in Breast Cancer.

Authors:  Bei Li; Rongxin Geng; Qi Wu; Qian Yang; Si Sun; Shan Zhu; Zhiliang Xu; Shengrong Sun
Journal:  Front Oncol       Date:  2020-03-12       Impact factor: 6.244

9.  Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity.

Authors:  Sara Verdura; Elisabet Cuyàs; Eric Cortada; Joan Brunet; Eugeni Lopez-Bonet; Begoña Martin-Castillo; Joaquim Bosch-Barrera; José Antonio Encinar; Javier A Menendez
Journal:  Aging (Albany NY)       Date:  2020-01-04       Impact factor: 5.682

Review 10.  Breast radiotherapy in elderly women: myths, controversies, and current techniques in the adjuvant setting.

Authors:  Ana Aurora Díaz Gavela; Blanca Vaquero Barrón; Elia Del Cerro Peñalver; Felipe Couñago
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.